Jay Eastman

Jay Eastman is chair of the board of the T1D Fund, the venture philanthropy fund launched in 2016 as the first scaled venture fund for cure-oriented type 1 diabetes therapies. Now operating as a Breakthrough T1D venture, the Fund makes equity investments in early-stage companies. In that role he directs how it co-invests philanthropic capital alongside venture capital and biopharma partners into companies pursuing T1D treatments, prevention, and cures. Proceeds from successful exits are redeployed into new investments. In 2025 he announced a new capital raise intended to enable larger, higher-conviction investments in promising T1D companies. He describes the Fund as having far surpassed its founders' initial expectations in bridging gaps in T1D drug development.

Affiliation

Chair, T1D Fund Board of Directors

Location

New York, New York, U.S.